Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with moderate to severe Ulcerative Colitis (a type of inflammatory bowel disease) and whose doctor has decided to prescribe them a medication called Risankizumab (RZB) as part of their normal medical care, following Japanese approved guidelines.
- People whose doctor made the decision to prescribe Risankizumab before and separately from any involvement in this study.
- People who are able to give voluntary written consent before any study activities begin. For anyone under 18 years old, a parent or legal guardian must be willing to provide written consent on their behalf.
- People who are able to understand the study requirements, communicate with the research team, and use a smartphone to regularly complete health questionnaires — including after Risankizumab treatment has ended.
- People who have never previously been treated with Risankizumab.
- People who are not currently taking part in another clinical intervention study (participating in observational studies or patient registries is acceptable).
Who may not be able to join:
- People who do not meet the inclusion criteria listed above (the trial documentation does not list separate exclusion criteria beyond this).
(As no additional exclusion criteria were provided in the source document, confirm with the trial site whether any further restrictions apply.)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: +81-3-4577-1111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the achievement of clinical remission per Partial Adapted Mayo Score of Risankizumab treatment in participants with moderate to severe Ulcerative Colitis (UC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.